Pharmaceutical Chemistry

Pharmaceutical Biotechnology and Tissue Engineering

The last few years have been a positive period overall for both the pharmaceutical and biotechnology industries. Most importantly, there has been a renaissance with regard to the increase in the number of new drugs approved and under development for the two segments of the business.

Many of these innovations are driven by new research methods and the growth of new therapeutic options, such as immune-related oncology drugs, personalized medicine, stem cells, and biologics. We are also witnessing the development of a greater number of drugs that cure diseases rather than just extend life.

The valuations of pharma and biotech companies in the public and M&A markets soared up until August/September of this year in part because of these positive developments. More recently, there has been a setback in public valuations due to the negative publicity about drug pricing.